Pandey Swaroop Kumar, Anand Uttpal, Siddiqui Waseem A, Tripathi Renu
Department of Life Sciences, The National Institute for Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.
Department of Life Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.
Adv Med. 2023 Mar 14;2023:5060665. doi: 10.1155/2023/5060665. eCollection 2023.
Malaria continued to be a deadly situation for the people of tropical and subtropical countries. Although there has been a marked reduction in new cases as well as mortality and morbidity rates in the last two decades, the reporting of malaria caused 247 million cases and 619000 deaths worldwide in 2021, according to the WHO (2022). The development of drug resistance and declining efficacy against most of the antimalarial drugs/combination in current clinical practice is a big challenge for the scientific community, and in the absence of an effective vaccine, the problem becomes worse. Experts from various research organizations worldwide are continuously working hard to stop this disaster by employing several strategies for the development of new antimalarial drugs/combinations. The current review focuses on the history of antimalarial drug discovery and the advantages, loopholes, and opportunities associated with the common strategies being followed for antimalarial drug development.
疟疾对于热带和亚热带国家的人民来说仍然是一种致命的状况。尽管在过去二十年里新病例以及死亡率和发病率都有显著下降,但据世界卫生组织(2022年)报告,2021年全球疟疾报告病例达2.47亿例,死亡61.9万人。在当前临床实践中,耐药性的发展以及大多数抗疟药物/联合用药疗效的下降,对科学界来说是一个巨大挑战,而且在缺乏有效疫苗的情况下,问题变得更加严重。世界各地不同研究机构的专家们一直在不懈努力,通过采用多种策略来开发新的抗疟药物/联合用药,以阻止这场灾难。本综述重点关注抗疟药物发现的历史,以及当前抗疟药物开发所采用的常见策略的优势、漏洞和机遇。